3.12
+0.19(+6.48%)
Currency In USD
| Previous Close | 2.93 |
| Open | 2.92 |
| Day High | 3.17 |
| Day Low | 2.87 |
| 52-Week High | 5.31 |
| 52-Week Low | 1.84 |
| Volume | 1.11M |
| Average Volume | 1.3M |
| Market Cap | 159.45M |
| PE | -2.11 |
| EPS | -1.48 |
| Moving Average 50 Days | 2.65 |
| Moving Average 200 Days | 3.07 |
| Change | 0.19 |
If you invested $1000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, it would be worth $0.53 as of September 10, 2025 at a share price of $3.12. Whereas If you bought $1000 worth of Achieve Life Sciences, Inc. (ACHV) shares 5 years ago, it would be worth $387.58 as of September 10, 2025 at a share price of $3.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
GlobeNewswire Inc.
Sep 03, 2025 12:30 PM GMT
Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire Inc.
Jul 29, 2025 12:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treat
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025
GlobeNewswire Inc.
Jul 24, 2025 12:30 PM GMT
SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treat